Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points-Reference-Cited by-同舟云学术

Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points

Published:2022-02 Issue:2 Volume:11 Page:109-120
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Law Ernest¹^ORCID,Gavanji Roya²^ORCID,Walsh Sarah³^ORCID,Haltner Anja³^ORCID,McTavish Rebecca²,Cameron Chris³^ORCID

Affiliation:

1. Pfizer, New York, NY 10017, USA

2. EVERSANA, Burlington, Ontario, L7N 3H8, Canada

3. EVERSANA, Sydney, Nova Scotia, B1P 1C6, Canada

Abstract

Aim: To assess the relative impact of palbociclib plus fulvestrant (PAL + FUL) and abemaciclib plus fulvestrant (ABEM + FUL) on patient-reported outcomes in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Patients & methods: Anchored matching-adjusted indirect comparisons were conducted using individual patient data from PALOMA-3 (PAL + FUL) and summary-level data from MONARCH-2 (ABEM + FUL). Outcomes included the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30) and its breast cancer-specific module (QLQ-BR23). Results: Significantly different changes from baseline favoring PAL + FUL compared with ABEM + FUL were observed in global quality of life (6.95 [95% CI: 2.19–11.71]; p = 0.004) and several functional/symptom scales, including emotional functioning, nausea/vomiting, appetite loss, diarrhea and systemic therapy side effects. Conclusion: PAL + FUL was associated with more favorable patient-reported outcomes than ABEM + FUL in patients with HR+/HER2- advanced breast cancer.

Funder

Pfizer, Inc.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer-2021-0221

Reference36 articles.

1. United States Food & Drug Administration. Drugs@FDA: FDA-approved drugs - palbociclib (IBRANCE) (2019). http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&var ApplNo=207103

2. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

3. United States Food & Drug Administration. Drugs@FDA: FDA-approved drugs - ribociclib (KISQALI) (2020). http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209092

4. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

5. United States Food & Drug Administration. Drugs@FDA: FDA-approved drugs - abemaciclib (VERZENIO) (2020). http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208716

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer;Scientific Reports;2024-04-30

2. Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey;The Oncologist;2023-07-31

3. Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story;Journal of Comparative Effectiveness Research;2023-06

4. Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant;Journal of Comparative Effectiveness Research;2023-06

5. Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review;Journal of Oncology Pharmacy Practice;2023-04-06